Teijin Ltd Regenerative Medicine Business Briefing Transcript
This is Jun Suzuki of Teijin. Thank you for joining us in our regenerative medicine business briefing today. It gives us a great pleasure to have so many participants.
As you are aware, on January 29 of this year, Teijin announced the Board decision to acquire the shares in J-TEC through a tender offer. The stock purchase was carried out from February 1 to March 2 and was successfully completed as originally planned, making Teijin the parent company of J-TEC. Following the closing in March, we embarked on more detailed official studies on how best to improve the corporate value of both Teijin and J-TEC.
When we made the internal decision to join hands with J-TEC more than a year ago, we already had a clear vision regarding the direction of the business that is to pursue regenerative medicine using autologous cell as the alternate of tailor-made medicine. Furthermore, we did envision that this business could make the big leap through leveraging Teijin's capabilities in health care, materials
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
